AptarGroup Q1 2022 Earnings Report
Key Takeaways
AptarGroup reported a 9% increase in sales to $845 million, with core sales up 13%. The company experienced double-digit core sales growth in each segment. Reported earnings per share were $0.93, and adjusted earnings per share were $0.96.
Reported sales grew 9% and core sales grew 13% with double-digit core growth in each segment.
Pharma segment posted sales growth in all markets including the prescription drug division as demand for allergic rhinitis and asthma devices began to recover.
Reported earnings per share of $0.93 compared to $1.24 in the prior year.
Adjusted earnings per share of $0.96 compared to $1.05 in the prior year.
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Forward Guidance
Aptar expects earnings per share for the second quarter of 2022, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.92 to $1.02.
Positive Outlook
- We are moving forward into the post-pandemic era and we feel very good about the way our businesses are positioned for long-term growth.
- Looking forward to the second quarter, we expect the broad based momentum from the first quarter to continue with growth in each segment
- Including strong growth of our prescription drug device business
- We will continue to manage our operations efficiently
- We mitigate rising costs through pricing initiatives and cost containment.
Challenges Ahead
- Lower demand for at-home COVID-19 tests.
- The war in Ukraine and the COVID-19 outbreak in China are expected to have some impact on our business in the respective regions
- Visibility remains highly uncertain.
- Guidance is based on an effective tax rate range of 27% to 29%
- Currency translation effects
Revenue & Expenses
Visualization of income flow from segment revenue to net income